Point‐Of‐Care Ultra‐Portable Single‐Molecule Bioassays for One‐Health

Abstract

AbstractScreening asymptomatic organisms (humans, animals, plants) with a high‐diagnostic accuracy using point‐of‐care‐testing (POCT) technologies, though still visionary holds great potential. Convenient surveillance requires easy‐to‐use, cost‐effective, ultra‐portable but highly reliable, in‐vitro‐diagnostic devices that are ready for use wherever they are needed. Currently, there are not yet such devices available on the market, but there are a couple more promising technologies developed at readiness‐level 5: the Clustered‐Regularly‐Interspaced‐Short‐Palindromic‐Repeats (CRISPR) lateral‐flow‐strip tests and the Single‐Molecule‐with‐a‐large‐Transistor (SiMoT) bioelectronic palmar devices. They both hold key features delineated by the World‐Health‐Organization for POCT systems and an occurrence of false‐positive and false‐negative errors <1–5% resulting in diagnostic‐selectivity and sensitivity >95–99%, while limit‐of‐detections are of few markers. CRISPR‐strip is a molecular assay that, can detect down to few copies of DNA/RNA markers in blood while SiMoT immunometric and molecular test can detect down to a single oligonucleotide, protein marker, or pathogens in 0.1mL of blood, saliva, and olive‐sap. These technologies can prospectively enable the systematic and reliable surveillance of asymptomatic ones prior to worsening/proliferation of illnesses allowing for timely diagnosis and swift prognosis. This could establish a proactive healthcare ecosystem that results in effective treatments for all living organisms generating diffuse and well‐being at efficient costs.